Clinical trials: Prevention of Venous Thromboembolism
Dose Adjustment of Enoxaparin in ICU Patients
Anti-factor Xa Based Venous Thromboembolism Prophylaxis
Introduction: Venous thromboembolism (VTE) in the intensive care unit (ICU) is associated with significant morbidity and mortality therefore prevention is imperative to reduce its burden.
- Trial name
- NCT05221879
- Testing
- Dose adjustment of Enoxaparin in patients with sub-therapuetic (prophylactic) levels of factor 10a
- Where
- Israel
- Volunteers
- 75 people
- Sponsor
- Meir Medical Center
Thromboembolism, Arthroplasty Replacement, Knee
Safety Study of Stopping Thromboprophylaxis Based on Ultrasound Results After Total Knee Replacement
The purpose of this study is to determine whether stopping Low Molecular Weight Heparin (LMWH) thromboprophylaxis is safe after total knee joint replacement.
- Trial name
- NCT00362492
- Testing
- Bilateral ultrasound examination 7+/- 2 after surgery
- Where
- 17 sites in France
- Volunteers
- 850 people
- Sponsor
- University Hospital, Caen
Venous Thrombosis (Disorder)
Patient Education Bundle vs. Nurses Feedback and Coaching to Prevent Missed Doses of VTE Prophylaxis
VTE associated harm is underappreciated among hospitalized patients and may be associated with missed doses of VTE prophylaxis medications.
- Trial name
- ENACT (NCT03367364)
- Testing
- Patient education bundle (PEB),, Nurse feedback and coaching (NFC)
- Where
- United States
- Volunteers
- 9,657 people
- Sponsor
- Johns Hopkins University
Venous Thromboembolism
Multicenter Registry for Effectiveness Analysis of ActiveCare+S.F.T® Mobile Compression Device for Thrombosis Prevention in Hip and Knee Arthroplasty
Venous thromboembolic events (VTE), either deep vein thromboses or pulmonary emboli, are important complications in patients undergoing knee or hip arthroplasty.
- Trial name
- ACOR (NCT01984190)
- Where
- 10 sites in United States
- Volunteers
- 411 people
- Sponsor
- Medical Compression Systems
Cancer, VTE (Venous Thromboembolism)
DOAC - Dosing Options in AntiCoagulation Prophylaxis
Blood clots, also known as venous thromboembolism (VTE), are a common and serious complication for people with cancer. They can lead to pain, hospitalizations, delayed cancer treatment, and even death.
- Trial name
- DOAC (NCT07005024)
- Testing
- Apixaban 2.5 mg twice daily, Apixaban 5 mg once daily, No anticoagulation
- Where
- United States
- Volunteers
- 996 people
- Sponsor
- University of Vermont
Arthroplasty, Replacement, Prevention of Venous Thromboembolism
Treatment of Patients Undergoing Primary Unilateral Elective Total Knee or Hip Replacement With Dabigatran Etexilate
To supplement the current evidence of the effect of Pradaxa® (dabigatran etexilate) on coagulation parameters, including a calibrated thrombin time test, in patients with moderate renal impairment undergoing elective total hip…
- Conditions
- Arthroplasty, Replacement, Prevention of Venous Thromboembolism, Moderate Renal Impairment (CrCl 30-50 mL/Min)
- Trial name
- NCT01184989
- Testing
- Dabigatran etexilate
- Where
- 10 sites in Austria, Canada and 4 more
- Volunteers
- 142 people
- Sponsor
- Boehringer Ingelheim
Venous Thromboembolism
Examining the Benefit of Graduated Compression Stockings in the Prevention of vEnous Thromboembolism in Low-risk Surgical Patients
Hospital acquired thrombosis describes blood clots that form in the legs and lungs after someone is treated in hospital. Clots in the leg can cause swelling, pain and other problems.
- Trial name
- PETS (NCT05347550)
- Testing
- Graduated Compression Stockings - Thromboembolic deterrent stockings
- Where
- 9 sites in United Kingdom
- Volunteers
- 21,472 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Venous Thromboembolism
Study to Compare the Effectiveness of Rivaroxaban (Xarelto) Versus Low-molecular-weight Heparin (LMWH) and Phenprocoumon for the Treatment and Secondary Prevention of Venous Thromboembolism in Routine Clinical Practice in Germany
Researcher in this study want to compare the effectiveness of Rivaroxaban (Xarelto) versus low-molecular-weight heparin (LMWH) and phenprocoumon for the treatment and secondary prevention of venous thromboembolism by evaluating…
- Trial name
- NCT04444804
- Testing
- Rivaroxaban (Xarelto, BAY 59-7939), LMWH and Phenprocoumon
- Where
- Germany
- Volunteers
- 22,153 people
- Sponsor
- Bayer
Total Knee Replacement Surgeries
Risk Stratification Procedure for Thromboembolism Prophylaxis
The main objective for this study is validation for the proposed risk stratification tool, by evaluating the clinical outcomes for its use post TKR Surgeries. For this objective, the design that is used is Randomized Trial.
- Trial name
- NCT04031859
- Testing
- acetylsalicylic acid
- Where
- Saudi Arabia
- Volunteers
- 242 people
- Sponsor
- Ministry of Health, Saudi Arabia
Venous Thromboembolism, Cancer
Tinzaparin for Primary Treatment and Extended Secondary Prophylaxis of Venous Thromboembolism in Patients With Cancer
In this study the investigators will determine the safety and effectiveness of Tinzaparin in preventing blood clots for up to 12 months of treatment.
- Trial name
- NCT00981903
- Testing
- Tinzaparin sodium
- Where
- 2 sites in United States
- Volunteers
- 131 people
- Sponsor
- University of Southern California
Pulmonary Embolism, Deep Vein Thrombosis
Angel® Catheter Early Feasibility Clinical Study
The primary objective of this clinical trial is to obtain initial insights into the safety of the Angel® Catheter in critically ill subjects with high risk of venous thromboembolism (VTE) disease AND who are not receiving…
- Conditions
- Pulmonary Embolism, Deep Vein Thrombosis, Venous Thromboembolism
- Trial name
- NCT01847196
- Testing
- Angel® Catheter
- Where
- 4 sites in United States
- Volunteers
- 6 people
- Sponsor
- BiO2 Medical
Venous Thromboembolism
Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement Surgery
The primary objective was to demonstrate the dose-response of Semuloparin sodium (AVE5026) for the prevention of Venous Thromboembolism [VTE] in patients undergoing total knee replacement [TKR] surgery.
- Trial name
- TREK (NCT00331838)
- Testing
- Semuloparin sodium, Enoxaparin sodium
- Where
- 19 sites in Argentina, Bulgaria and 17 more
- Volunteers
- 705 people
- Sponsor
- Sanofi
Venous Thromboembolism, Hemorrhage
A Clinical Cohort Study of Safety and Effectiveness of Venous Thromboembolism Prophylaxis in Critical Ill Patients
The purpose of this study is to analyze the effect of the prophylaxis of venous thromboembolism in the critical ill patients, and at the same time, to find out the risk of venous thromboembolism and hemorrhage events occurred…
- Trial name
- VTEH (NCT02213978)
- Where
- China
- Volunteers
- 1,114 people
- Sponsor
- Beijing Chao Yang Hospital
Venous Thrombosis, Pulmonary Embolism
Extended Out-of-hospital Low-molecular-weight Heparin Prophylaxis Against DVT and PE in Patients Undergoing Major Lung Resection
Postoperative venous thromboembolism (VTE) is a significant health-care problem, resulting in significant morbidity, mortality and resource utilization. The true incidence is unknown, and may range from 1% to 15%.
- Conditions
- Venous Thrombosis, Pulmonary Embolism, Lung Neoplasms
- Trial name
- NCT02258958
- Where
- 2 sites in Canada
- Volunteers
- 150 people
- Sponsor
- McMaster University
Venous Thromboembolism, Urologic Cancer
VTE Prevention With Rivaroxaban in Genitourinary Cancer Patients Receiving Systemic Therapy
Patients with genitourinary cancers (ex: bladder, testicular, kidney) are at high risk of developing blood clots if they receive systemic therapy (ex: chemotherapy, immunotherapy).
- Trial name
- PREVENT-GU (NCT05920343)
- Testing
- Rivaroxaban 10 MG
- Where
- Canada
- Volunteers
- 120 people
- Sponsor
- Ottawa Hospital Research Institute
Venous Thromboembolism, Deep Vein Thrombosis
OsciPulse Device for the Prevention of VTE
This is a Phase 2 safety and tolerability trial that will take place in two parts. Part one of the trial will determine the tolerability of the OsciPulse device on healthy subjects who wear the device for up to three hours.
- Conditions
- Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Thromboembolisms
- Trial name
- NCT04625673
- Testing
- OsciPulse
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Venous Thromboembolism, Digital Health
Smart Technology Facilitated Patient-centered Venous Thromboembolism Management
Smart technologies, such as wearable devices, mobile technologies, and artificial intelligence, are being investigated for use in health management.
- Conditions
- Venous Thromboembolism, Digital Health, Health Education
- Trial name
- SmaVTE-RCT (NCT06350331)
- Testing
- mobile venous thromboembolism application (mVTEA)
- Where
- China
- Volunteers
- 256 people
- Sponsor
- Navy General Hospital, Beijing
Myeloma, Venous Thromboembolism
Evaluation of the Use of Apixaban in Prevnetion of Thromboembolic Disease in Patients With Myeloma Trated With iMiDs
To evaluate: the incidence of venous thromboembolic event (VTE) the incidence of hemorrhagic complications, In a population of patients with myeloma who are treated with IMiDs and require thromboprophylaxis for 6 months, using an…
- Trial name
- MYELAXAT (NCT02066454)
- Testing
- Apixaban
- Where
- 19 sites in France
- Volunteers
- 108 people
- Sponsor
- University Hospital, Grenoble
Knee Arthroplasty, Total
FactOr XIa inhibiTion for the pRevention of venOus Thromboembolism in Patients Undergoing Total Knee Arthroplasty
This study was to compare the study drug BAY1213790 to existing therapies, i.e. enoxaparin or apixaban, for the prevention of blood clotting and safety in patients undergoing total knee arthroplasty (TKA).
- Trial name
- FOXTROT (NCT03276143)
- Testing
- Enoxaparin, Apixaban, BAY1213790
- Where
- 54 sites in Bulgaria, Canada and 11 more
- Volunteers
- 813 people
- Sponsor
- Bayer
Venous Thromboembolism, Digital Health
Smart Technology Facilitated Patient-centered Venous Thromboembolism Management
Smart technologies, such as wearable devices, mobile technologies, and artificial intelligence, are being investigated for use in health management.
- Conditions
- Venous Thromboembolism, Digital Health, Health Education
- Trial name
- SmaVTE-COR (NCT06350344)
- Testing
- mobile venous thromboembolism application (mVTEA)
- Where
- China
- Volunteers
- 2,353 people
- Sponsor
- Navy General Hospital, Beijing